Insmed
Commercializes rare pulmonary disease medicines while developing pulmonary, antibody and gene therapies.
$118.65
After-hours close+0.15 (+0.13%)
At close$118.50(−2.38%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | −$0.37 | — | — |
| Aug 2026 | −$0.67 | −$0.06 | +91.1% |
| May 2026 | −$0.96 | −$0.76 | +21.1% |
| Feb 2026 | −$1.07 | −$1.54 | −43.9% |
| Oct 2025 | −$1.33 | −$1.75 | −31.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | −$0.37 | — | — | $501.2M | — | — |
| Aug 6, 2026 | −$0.67 | −$0.06 | +91.1% | $395.5M | $425.5M | +7.6% |
| May 7, 2026 | −$0.96 | −$0.76 | +21.1% | $300.8M | $306.0M | +1.7% |
| Feb 19, 2026 | −$1.07 | −$1.54 | −43.9% | $231.2M | $263.8M | +14.1% |
| Oct 30, 2025 | −$1.33 | −$1.75 | −31.6% | $115.4M | $142.3M | +23.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 20, 2025 | ||||||
| Oct 31, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Feb 22, 2024 | ||||||
| Oct 26, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 4, 2023 | ||||||
| Feb 23, 2023 | ||||||
| Oct 27, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 5, 2022 | ||||||
| Feb 17, 2022 | ||||||
| Oct 28, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 6, 2021 | ||||||
| Feb 25, 2021 | ||||||
| Oct 29, 2020 | ||||||
| Aug 6, 2020 | ||||||
| Apr 30, 2020 | ||||||
| Feb 25, 2020 | ||||||
| Oct 30, 2019 | ||||||
| Aug 1, 2019 | ||||||
| May 7, 2019 | ||||||
| Feb 22, 2019 | ||||||
| Oct 30, 2018 | ||||||
| Aug 2, 2018 | ||||||
| May 2, 2018 | ||||||
| Feb 23, 2018 | ||||||
| Nov 2, 2017 | ||||||
| Aug 3, 2017 | ||||||
| May 3, 2017 | ||||||
| Feb 23, 2017 | ||||||
| Nov 3, 2016 | ||||||
| Aug 4, 2016 | ||||||
| May 5, 2016 | ||||||
| Feb 25, 2016 | ||||||
| Nov 6, 2015 | ||||||
| Aug 6, 2015 | ||||||